Drug Price Trends for NDC 69238-2261

Average Pharmacy Cost for 69238-2261

Drug Name	NDC	Price/Unit ($)	Unit	Date
VANCOMYCIN 250 MG/5 ML ORAL SOL	69238-2261-07	0.63822	ML	2026-03-18
VANCOMYCIN 250 MG/5 ML ORAL SOL	69238-2261-07	0.63158	ML	2026-02-18
VANCOMYCIN 250 MG/5 ML ORAL SOL	69238-2261-07	0.60652	ML	2026-01-21
VANCOMYCIN 250 MG/5 ML ORAL SOL	69238-2261-05	0.80070	ML	2025-12-17
VANCOMYCIN 250 MG/5 ML ORAL SOL	69238-2261-03	2.90936	ML	2025-12-17

Best Wholesale Price for NDC 69238-2261

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 69238-2261

Last updated: February 13, 2026

Overview

The drug identified with NDC 69238-2261 is Epclusa, marketed by Gilead Sciences. It is a fixed-dose combination therapy of sofosbuvir and velpatasvir indicated for the treatment of chronic hepatitis C virus (HCV) infection across all genotypes (1-6). This report examines the current market status, competitive landscape, pricing trends, and future price projections.

Market Position and Therapeutic Context

• Indications: Chronic hepatitis C, including all genotypes, in adult patients.
• Market launch: 2016.
• Treatment landscape:
  • Competition from other direct-acting antivirals (DAAs) such as Harvoni (ledipasvir/sofosbuvir), Zepatier (elbasvir/grazoprevir), Mavyret (glecaprevir/pibrentasvir), and Vosevi (sofosbuvir/velpatasvir/voxilaprevir).
  • Increasing generic availability in some regions; however, Epclusa retains exclusivity and market share in the U.S.

Market Size and Demand Drivers

• Prevalence: Approximately 2.4 million people in the U.S. live with HCV; worldwide estimates reach 58 million.
• Therapy adherence: High cure rates (>95%) with few adverse effects.
• Pricing: High price point initially set at $74,760 for a 12-week course in the U.S.
• Insurance impact: Reimbursement conditional on prior authorization, negotiations, and discounts.

Pricing Trends and Historical Data

Year	Average Wholesale Price (AWP) / Unit	Notes
2016	$74,760 for 12-week course	Launch price in the U.S.
2018	Negotiated discounts; actual paid prices lower	PBMs and insurers negotiated substantial rebates.[1]
2020	$54,000–$65,000 per treatment course	Variability across providers and regions
2022	Approx. $39,000–$45,000 per course	Increased generic competition in some markets

Price Projections

• Short-term (next 1–2 years):
  Prices are expected to decline due to patent expirations in key markets, increased competition, and policy shifts favoring cost containment.

  • U.S. prices potentially drop to $30,000–$40,000 per course through negotiations and value-based pricing arrangements.
  • In less regulated markets, prices might vary significantly, with some regions paying less due to local generics and price controls.

• Medium-term (3–5 years):

  • Dominance of generics in some regions could reduce prices further to below $20,000.
  • Innovation in HCV therapy or therapeutic repositioning could alter market dynamics.
  • Gilead may introduce targeted pricing based on patient risk, genotype, or treatment history.

Key Factors Influencing Prices

• Patent expirations: Expected from 2028 in major markets.
• Generic entry: Limited currently but likely in regions like India and Europe by 2025.
• Reimbursement policies: Changes in U.S. Medicare and Medicaid utilization impact pricing strategies.
• Global market access: Differentiated by country income level; low-resource settings see significantly lower prices.

Competitive Landscape

Drug	Company	Approved Since	Market Share in U.S.	List Price	Notes
Epclusa	Gilead Sciences	2016	Leading among pan-genotypic agents	~$74,760	First all-Genotype treatment, high efficacy
Mavyret	AbbVie	2017	Rapid growth in U.S.	~$26,400	Shorter treatment duration, lower cost
Zepatier	Merck	2016	Moderate	~$54,600	Genotype-specific, less used in current market
Vosevi	Gilead Sciences	2017	Niche in retreat	~$75,000	Used post-failure or with resistance

Regulatory and Policy Impact

• Patent protections sustain high prices until expiration.
• Value-based contracts and rebate agreements influence net prices.
• Global health initiatives promote generic use and price reductions in low-income countries.

Summary

• The current market price for Epclusa reflects high initial pricing driven by R&D recovery and market exclusivity.
• Competitive pressures, patent expirations, and negotiations are driving prices downward.
• Projections indicate significant price reductions over a 3-5 year horizon, especially with increased generic penetration outside the U.S.
• Pipeline innovations or policy changes could influence future pricing strategies.

---

Key Takeaways

• Original launch price was ~$74,760 per course; current net prices are often lower.
• Market entry of generics expected after patent expiry (around 2028 in major markets).
• Price declines due to competition, negotiations, and policies could reduce costs by over 50% in the next five years.
• Geographic disparities remain, with high-income countries paying more and emerging markets benefiting from lower prices.
• Patent protections, regional regulations, and health policies are primary determinants of future pricing trends.

---

FAQs

1. What is the current market price of Epclusa in the U.S.?
   Estimated net prices range from $30,000 to $40,000 per course after discounts and rebates.

2. When will generic versions likely enter the market?
   Patents are set to expire in key regions around 2028, with generic production potentially beginning shortly afterward.

3. How does Epclusa compete with other HCV treatments?
   It offers pan-genotypic efficacy, high cure rates, and a once-daily regimen, maintaining its market share despite rising competition from other DAAs with lower prices.

4. What factors could influence future prices?
   Patent status, generic entry, reimbursement policies, and innovation in therapeutic options.

5. Are there differences in pricing globally?
   Yes, prices vary significantly due to market regulations, negotiations, and licensing agreements, often being substantially lower outside the U.S.

---

References

[1] IQVIA National Sales Perspective, 2022.